- Home
- BIOA vs MPLT Comparison
BIOA vs MPLT Comparison
Compare BIOA & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIOA | MPLT |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | 64 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 856.3M | 811.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BIOA | MPLT |
|---|---|---|
| Price | $21.13 | $17.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $51.80 | $31.00 |
| AVG Volume (30 Days) | ★ 448.5K | 123.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $898.47 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.88 | $12.24 |
| 52 Week High | $24.00 | $21.55 |
Technical Indicators
Market Signals| Indicator | BIOA | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 55.10 | 48.19 |
| Support Level | $18.62 | $16.17 |
| Resistance Level | $22.25 | $20.20 |
| Average True Range (ATR) | 1.42 | 1.32 |
| MACD | -0.13 | 0.03 |
| Stochastic Oscillator | 67.45 | 29.47 |
Price Performance
Historical ComparisonAbout BIOA BioAge Labs Inc.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
About MPLT MapLight Therapeutics Inc.
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.